Privacy Policy
Signals Blog

Contributors

Categories

A double duty scaffold for cell delivery to the brain

Neurodegenerative diseases of the brain, such as Parkinson’s and Alzheimer’s, are a leading cause of disability in Canada, but despite the significant burden on patients, caregivers and the health-care system, we still lack a cure. An active area of research for these...

Right Turn: The wait is over

For nearly 2 million people, the restless nights, anxious days, over-caffeinated spiral is almost over. On April 14th, Orphan Black returns with its fourth season. A few Christmases ago, I compiled a list of television shows and movies that feature stem cells in a...

Update from the Clinic: February

Welcome to your Update from the Clinic for the month of February. bluebird made its debut in the oncology market and treated its first patient with a chimeric antigen receptor (CAR) product targeting a novel antigen. Ziopharm enrolled its first patient in a study...

Right Turn: Coming at you from a beach down south

We don’t need no education We don’t need no thought control No dark sarcasm in the classroom Teachers leave them kids alone Hey! teachers! leave the kids alone! All in all it’s just another brick in the wall. All in all you’re just another...

Cell Therapy Deal Review: February

Welcome to your deal review for the month of February. Astellas tied-off its acquisition of Ocata while GSK and Adaptimmune expanded their collaboration to develop cell-based immunotherapies. AVROBIO, a new cell and gene company based in Boston, Mass, and Toronto,...

Right Turn: Hurray for tissue engineering!

Tissue engineering is a key part of regenerative medicine (RM), but it sometimes feels like the poor cousin of stem cells. The Jan to big sister Marcia. That won’t be the case at the upcoming 10th World Biomaterials Congress (WBC2016), happening May 17-22 in Montreal,...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!